Clinical Trials Directory

Trials / Completed

CompletedNCT06426823

The Role of GIP in Postprandial Splanchnic Blood Flow Distribution and Metabolism in Patients With Type 2 Diabetes

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
10 (actual)
Sponsor
University of Copenhagen · Academic / Other
Sex
All
Age
20 Years – 80 Years
Healthy volunteers
Not accepted

Summary

This project will describe the mechanisms of action and the relative contributions of GIP to changes in gastrointestinal blood flow induced by oral glucose and endogenous GIP with the use of a receptor antagonists GIP(3-30)NH2 in patients with type 2 diabetes.

Detailed description

Each participant will attend four independent randomised experimental days in the MRI-scanner with intravenous infusion (hormone/placebo) and oral ingestion (glucose/water): An intravenous infusion of saline or GIP(3-30)NH2 starts at time point -20 minutes.The infusions are combined with an oral glucose tolerance test (75 gram of glucose dissolved in 250 ml water ingested orally) at time point 0 minutes on two of the experimental days (with and without GIP(3-30)NH2). MRI measurements are repeatedly performed and blood samples are drawn to be analysed for endocrine responses from the intestines, pancreas, and bones.

Conditions

Interventions

TypeNameDescription
OTHERSaline / placeboNaCl (9 mg/ml)
OTHERGIPR antagonist / study toolGIP(3-30)NH2

Timeline

Start date
2023-11-01
Primary completion
2026-03-16
Completion
2026-03-16
First posted
2024-05-23
Last updated
2026-03-18

Locations

1 site across 1 country: Denmark

Source: ClinicalTrials.gov record NCT06426823. Inclusion in this directory is not an endorsement.